Two Sigma Investments
UNCY icon

Two Sigma Investments’s Unicycive Therapeutics UNCY Stock Holding History

Two Sigma Investments’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,555
Closed -$72K – 4917
2021
Q3 		$72K Buy
+2,555
New +$73.3K ﹤0.01% 4119

Other funds holding UNCY

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return
AC
Ayrton Capital Westport, Connecticut $14.7M AUM 12.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FWM
Frontier Wealth Management Kansas City, Missouri $1.38B AUM 6.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tandem Capital Management Woodcliff Lake, New Jersey $200M AUM 25.01% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Two Sigma Investments's UNCY Position: Q4 2021 in Review

Two Sigma Investments sold out of Unicycive Therapeutics (UNCY) in Q4 2021, closing a stake of 2,555 shares — an estimated $72K sold.

Two Sigma Investments first reported a position in UNCY in Q3 2021 and held it in 1 quarter. The position peaked at $72K in Q3 2021. 11 funds tracked by Wall St. Rank hold UNCY as of Q4 2021.

  • Two Sigma Investments reported no remaining Unicycive Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Two Sigma Investments sold 2,555 Unicycive Therapeutics shares in Q4 2021, an estimated $72K.
  • Two Sigma Investments first reported a position in Unicycive Therapeutics in Q3 2021 and held it in 1 quarter.
  • Two Sigma Investments's Unicycive Therapeutics position peaked at $72K in Q3 2021.
  • 11 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q4 2021.

Based on Two Sigma Investments's 13F filing for Q4 2021, filed 14 Feb 2022.